LightPath Technologies, Inc. — Form 10-Q Summary
Period: Quarter and nine months ended March 31, 2020 (fiscal Q3 2020). The filing date is May 7, 2020. Although the request metadata says 2019 Q3, the filing itself covers 2020 Q3.
Business context
LightPath designs, manufactures, and sells optical components and assemblies, including precision molded optics (PMO), infrared products, and specialty products. Its operations span the United States, China, and Latvia, serving markets including medical, defense, telecommunications, industrial, and public safety.
Financial performance and position
| Metric | Three months ended March 31, 2020 | Nine months ended March 31, 2020 |
|---|---|---|
| Revenue | $8.71 million, up 10% year over year | $25.86 million, up 3% |
| Gross margin | $4.01 million; 46% of revenue, versus 39% | $10.33 million; 40% of revenue, versus 39% |
| Operating income (loss) | $1.06 million, versus $21,000 | $1.51 million, versus a $63,000 loss |
| Net income (loss) | $816,000, versus a $352,000 loss; $0.03 per diluted share | $210,000, versus a $919,000 loss; $0.01 per diluted share |
| Operating cash flow | Not presented for the quarter alone | $1.87 million, versus $26,000 |
| Capital expenditures | Not presented for the quarter alone | $1.51 million |
At March 31, 2020, cash and cash equivalents were $4.38 million, working capital was approximately $13.7 million, and total assets were $46.06 million. Total liabilities were $12.14 million. Loans payable were approximately $5.16 million net of debt costs (principal of approximately $5.23 million); finance and operating lease liabilities were also outstanding. The BankUnited term loan bore a 4.33% rate at quarter-end. No amounts were drawn on the $2 million revolving line or the discretionary $10 million guidance line. The company reported compliance with loan covenants.
Cash declined by $223,000 over the nine months. Operating cash flow of $1.87 million was partly offset by $1.32 million of investing outflows and $727,000 of financing outflows. More than half of cash was held by foreign subsidiaries.
Changes versus the prior comparable period
- Quarterly revenue increased 10%; PMO revenue rose 15% and infrared revenue rose 12%, while specialty revenue fell 22%. For the nine months, PMO rose 1%, infrared rose 6%, and specialty declined 2%.
- Quarterly gross margin improved to 46%, reflecting product mix, improved costs and operating performance after the Irvington facility relocation, and higher sales. Year-to-date margin was 40%, up one percentage point.
- Quarterly SG&A decreased 7%; nine-month SG&A decreased 8%, partly due to lower costs after the Irvington relocation and the absence of prior-year restructuring costs. Interest expense also declined following refinancing and loan principal paydown.
- Year-to-date income tax expense was $674,000, compared with a $40,000 tax benefit a year earlier. It included Chinese taxes and withholding tax on a $2 million intercompany dividend declared in December 2019 and paid by March 31, 2020.
- Adoption of lease accounting guidance on July 1, 2019 added operating lease right-of-use assets and liabilities to the balance sheet; the company reported no impact on income or cash flows from adoption.
Outlook, commentary, and risks
Management reported a 12-month sales backlog of approximately $20.0 million at March 31, up 17% from March 31, 2019 and 5% from the prior quarter. Based on backlog and quote activity, it expected revenue growth in both PMO and infrared products for the remainder of fiscal 2020. Management cited increased demand for thermal imaging products, including fever-detection applications, and expected capital expenditures for fiscal 2020 to be similar to fiscal 2019. These are expectations, not guarantees.
Management said operations had not experienced a significant direct COVID-19 impact as of the filing, manufacturing sites remained open, and the company had seen increased fever-detection demand. However, it could not estimate the pandemic’s future effects. Risks include weaker customer demand, supply-chain disruption, restrictions on operations, and broader economic and capital-market volatility. Management said it believed resources could withstand short-term impacts, but an extended impact could materially affect sales, earnings, and liquidity.
The company noted that continued liquidity depends on operating performance and access to capital; if efforts to improve cash flow and profitability fail, additional capital or strategic alternatives may be considered. Other operating risks include inventory conversion, material and labor costs, production yields, and the ability to fund capacity needs. No legal proceedings were reported.
Most important facts for investors to verify
- Whether the $20.0 million backlog converts to revenue on expected timing, particularly amid COVID-19-related demand and uncertainty.
- Whether gross-margin gains and improved BD6 production yields continue, and whether tariff, freight, or other cost pressures return.
- Cash availability and accessibility, given that more than half of cash was held overseas, alongside debt service and lease obligations.
- The effect of COVID-19 on demand, suppliers, operations, cash flow, and access to financing after the reporting date; the filing says the impact was not yet estimable.
- Tax expense and withholding-tax consequences of intercompany distributions, and ongoing compliance with BankUnited loan covenants.